There is strong evidence that disease progression, drug response and overall clinical outcomes of CML disease are not only decided by BCR/ABL1 oncoprotein but depend on accumulation of additional genetic and epigenetic aberrations. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.